TP III

General Information


DRACP ID  DRACP00852

Peptide Name   TP III

Sequence  KWCFRVCYRGICYRKCR

Sequence Length  17

UniProt ID  P18252 

PubChem CID  Not available

Origin  horseshoe crab Limulus polyphemus

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HL-60 Adult acute myeloid leukemia; Acute myeloid leukemia Leukemia IC50=5.0±0.4 μM MTT assay 48h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=13.7±1.3 μM MTT assay 48h 1
SK-BR-3 Breast adenocarcinoma Carcinoma IC50=27.5±0.8 μM MTT assay 48h 1
A549 Lung adenocarcinoma Carcinoma IC50=15.3±1.0 μM MTT assay 48h 1

Hemolytic Activity  Human red blood cells (hBRC): TP I lysed 20%, at a maximal concentration of 100 µM

Normal (non-cancerous) Cytotoxicity  HEK 293T: IC50=19.7±1.9 μM; HEF:IC50=14.1±1.2 μM; NHA: IC50=14.1±1.2 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  6PIP  6PI3 

Predicted Structure  DRACP00852

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C99H154N32O20S4

Absent amino acids  ADEHLMNPQST

Common amino acids  CR

Mass  252632

Pl  9.99

Basic residues  6

Acidic residues  0

Hydrophobic residues  4

Net charge  6

Boman Index  -5073

Hydrophobicity  -48.24

Aliphatic Index  40

Half Life 
  Mammalian: 3.5 hour
  Yeast: 10 min
  E.coli: >10 hour

Extinction Coefficient cystines  8730

Absorbance 280nm  545.63

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30486233

Title  Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III

Doi 10.3390/md16120466

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.